1. Home
  2. XLO

XLO

Xilio Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
-
.
-
-
%

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).

Founded: 2016 Country:
United States
United States
Employees: N/A City: WALTHAM
Market Cap: 45.4M IPO Year: 2021
Target Price: $7.00 AVG Volume (30 days): 1.2M
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.78 EPS Growth: N/A
52 Week Low/High: $0.49 - $3.45 Next Earning Date: 05-07-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): 150.00%

Share on Social Networks: